Evidence map›Paper›PMID 24921917›Full record

ArticleBritish journal of cancer2014

The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy.

Y Yu, X Zhang, S Hong, M Zhang, Q Cai, M Zhang, W Jiang, C Xu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Possible Risk Factors of Pulmonary Metastases in Patients With International Federation of Gynecology and Obstetrics Stage I Endometrioid-Type Endometrial Cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2017
    Article
  16. Article
  17. Article
  18. Review
  19. Liquid-based three-dimensional tumor models for cancer research and drug discovery.Experimental biology and medicine (Maywood, N.J.) · 2016
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Y Yu1] Obstetrics and Gynecology Hospital, Fudan University, No.419, Fang-Xie Road, Shanghai 200011, China [2] Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, No.138, Yi-Xueyuan Road, Shanghai 200032, China [3] Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, No. 413, Zhao-Jiabang Road, Shanghai 200011, China.
X Zhang1] Obstetrics and Gynecology Hospital, Fudan University, No.419, Fang-Xie Road, Shanghai 200011, China [2] Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, No.138, Yi-Xueyuan Road, Shanghai 200032, China [3] Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, No. 413, Zhao-Jiabang Road, Shanghai 200011, China.
S Hong1] Obstetrics and Gynecology Hospital, Fudan University, No.419, Fang-Xie Road, Shanghai 200011, China [2] Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, No.138, Yi-Xueyuan Road, Shanghai 200032, China [3] Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, No. 413, Zhao-Jiabang Road, Shanghai 200011, China.
M Zhang1] Obstetrics and Gynecology Hospital, Fudan University, No.419, Fang-Xie Road, Shanghai 200011, China [2] Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, No.138, Yi-Xueyuan Road, Shanghai 200032, China [3] Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, No. 413, Zhao-Jiabang Road, Shanghai 200011, China.
Q Cai1] Obstetrics and Gynecology Hospital, Fudan University, No.419, Fang-Xie Road, Shanghai 200011, China [2] Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, No.138, Yi-Xueyuan Road, Shanghai 200032, China [3] Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, No. 413, Zhao-Jiabang Road, Shanghai 200011, China.
M Zhang1] Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, No. 413, Zhao-Jiabang Road, Shanghai 200011, China [2] Department of Obstetrics and Gynecology, Hospital 411 of CPLA, Shanghai 200081, China.
W Jiang1] Obstetrics and Gynecology Hospital, Fudan University, No.419, Fang-Xie Road, Shanghai 200011, China [2] Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, No.138, Yi-Xueyuan Road, Shanghai 200032, China [3] Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, No. 413, Zhao-Jiabang Road, Shanghai 200011, China.
C Xu1] Obstetrics and Gynecology Hospital, Fudan University, No.419, Fang-Xie Road, Shanghai 200011, China [2] Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, No.138, Yi-Xueyuan Road, Shanghai 200032, China [3] Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, No. 413, Zhao-Jiabang Road, Shanghai 200011, China [4] Institute of Biomedical Sciences, Fudan University, Shanghai 200032, No.138, Yi-Xueyuan Road, Shanghai 200032, China.
Shanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer has the highest mortality rate of the gynaecological cancers. Although cisplatin (CDDP) is an effective treatment for ovarian cancer, recurrence is frequent and leads to death. The objective was to explore the role and possible mechanisms of platelet-activating factor receptor (PAFR) signalling in CDDP-treated ovarian cancer cells.

methodsThe upregulation of PAFR in CDDP-treated ovarian cancer cells was observed using realtime PCR and Western blot. The potential role of PAFR in modulating the CDDP sensitivity was assessed using a pharmacological inhibitor and siRNA knockdown. The PAFR-activated signalling pathways involved in cell responses to CDDP were assessed.

resultsCisplatin induced increased PAFR expression in two ovarian cancer cell lines. The upregulation of PAFR by CDDP correlated with the time-dependent accumulation of NF-κB and HIF-1α in the nucleus. The inhibition of PAFR sensitised the ovarian cancer cells to CDDP. The PI3K and ERK pathways lie downstream of activated PAFR in CDDP-treated cells and their inhibition enhanced CDDP sensitivity. Finally, co-treatment with a PAFR antagonist (Ginkgolide B) and CDDP markedly reduced tumour growth in an in vivo model of ovarian cancer.

conclusionsTogether, these findings suggest that PAFR is a novel and promising therapeutic target for sensitising ovarian cancer cells to CDDP.

Indexed as

AnimalsAntineoplastic AgentsAzepinesCell Line, TumorCell NucleusCisplatinCombined Modality TherapyDrug Resistance, NeoplasmFemaleGene ExpressionGene Knockdown TechniquesHumansHypoxia-Inducible Factor 1, alpha SubunitMAP Kinase Signaling SystemMice, NudeOvarian NeoplasmsAntineoplastic AgentsAzepinesCisplatinHIF1A protein, humanHypoxia-Inducible Factor 1, alpha Subunitplatelet activating factor receptorPlatelet Membrane GlycoproteinsReceptors, G-Protein-CoupledRELA protein, humanTranscription Factor RelATriazolesWEB 2086

Identifiers

PMID24921917
PMCPMC4119987
OpenAlexW2002085186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.